View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 24, 2022

Altamira reaches target enrolment in acute Covid-19 nasal spray trial

The trial of Bentrio nasal spray in acute Covid-19 patients is being carried out in Bulgaria and North Macedonia.

Altamira Therapeutics has reached the target enrolment of 136 participants in its COVAMID clinical trial analysing the Bentrio nasal spray in acute Covid-19 patients.

An over the counter (OTC) drug-free nasal spray, Bentrio is said to offer protection from allergens and airborne viruses. 

Being carried out in Bulgaria and North Macedonia, the placebo-controlled, randomised trial will assess the safety, tolerability and efficacy of the Bentrio nasal spray in acute Covid-19 patients. 

Furthermore, the potential of Bentrio will be evaluated to cut down the SARS-CoV-2 viral load in the nose, reduce signs and symptoms of Covid-19 and reduce the occurrence of hospitalisations linked to Covid-19. 

Participants will be categorised into a 2:1:1 ratio to receive either Bentrio or a placebo or no treatment for ten days.

These subjects will be followed up for another ten days in the observation phase. 

After concluding the data entry and verification, the company will carry out a pre-specified blinded interim assessment to check if the preliminary assumptions for the statistical powering of the trial have been satisfied. 

On confirming this, Altamira plans to report top-line findings from the trial in the third quarter of this year. 

If the interim analysis indicates that a bigger sample size is needed, the company will continue subject enrolment to up to 180 patients and the top-line findings will be reported in the fourth quarter of this year.

On obtaining positive data from the trial, the company intends to seek a product label expansion for Bentrio to include viral infections in regions needing supportive clinical data. 

Altamira Therapeutics founder, chairman and CEO Thomas Meyer said: “After having already demonstrated Bentrio’s effectiveness and utility in several clinical studies in allergic rhinitis, this is a significant milestone in our clinical development of Bentrio in viral infections. 

“Given its unique triple mode of action and versatility against various types of viruses, we consider Bentrio well-positioned to help protect people in a world with many challenges from existing or evolving airborne viruses.”

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena